Zolimidine, an imidazopyridine analogue, is an orally bioactive antiulcer agent. Zolimidine stimulates mucus secretion by intestinal mucosal cells and strengthens the intestinal wall's ability to resist ulcers. Zolimidine demonstrated gastroprotective effects in duodenal ulcer studies.

Physicochemical Properties

Molecular Formula	C14H12N2O2S
Molecular Weight	272.32
Exact Mass	272.062
CAS #	1222-57-7
PubChem CID	14652
Appearance	Light yellow to brown solid powder
Density	1.31 g/cm3
Index of Refraction	1.653
LogP	3.485
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	2
Heavy Atom Count	19
Complexity	410
Defined Atom Stereocenter Count	0
InChi Key	VSLIUWLPFRVCDL-UHFFFAOYSA-N
InChi Code	InChI=1S/C14H12N2O2S/c1-19(17,18)12-7-5-11(6-8-12)13-10-16-9-3-2-4-14(16)15-13/h2-10H,1H3
Chemical Name	2-(4-methylsulfonylphenyl)imidazo[1,2-a]pyridine
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vivo	In rats given indomethacin (5 mg/kg/day for 8 days, rectal) as a cause of intestinal ulceration, zolimidine (200 mg/kg; oral) lowers the occurrence of this condition [2]. In guinea pigs, carrageenan (added to drinking water; 5% for 40 days) causes intestinal ulcers; zolimidine (added to the food; 1% lowers the occurrence of these ulcers) [2].
References	[1]. The effect of zolimidine, imidazopyridine-derivate, on the duodenal ulcer healing. Scand J Gastroenterol Suppl. 1979;54:44. [2]. Protective action of zolimidine against two different types of experimental intestinal ulcers. Farmaco, Edizione Pratica (1978), 33(2), 68-79.
Additional Infomation	Zolimidine is a member of imidazoles.

Solubility Data

Solubility (In Vitro)

DMSO: 50 mg/mL (183.61 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (9.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.6722 mL	18.3608 mL	36.7215 mL
	5 mM	0.7344 mL	3.6722 mL	7.3443 mL
	10 mM	0.3672 mL	1.8361 mL	3.6722 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.